Prescription Drug Rehab for Couples

If anyone is in immediate danger, call 911. For mental health and substance use crisis support, call or text 988 (Suicide and Crisis Lifeline). To speak confidentially with a care navigator about prescription drug rehab for couples, call (888) 500-2110 — available 24/7.

When Prescription Drug Use Becomes a Couples Crisis

Prescription drug addiction is one of the most common — and most misunderstood — forms of substance use disorder in the United States. According to the National Institute on Drug Abuse (NIDA), roughly 18 million Americans misuse prescription medications in a given year, with opioids, benzodiazepines, and stimulants accounting for the majority of cases. When dependence develops inside a relationship, its effects ripple outward: trust erodes, communication breaks down, enabling behaviors take root, and both partners may find themselves trapped in patterns that feel impossible to escape.

Some couples reach out because both partners are dependent on prescription drugs — sometimes the same substance, sometimes different ones. Others contact us because one partner’s opioid or benzodiazepine use has become unmanageable and the relationship is at a breaking point. In either case, the clinical and relational dimensions of recovery are inseparable. Treating only the substance without addressing the relationship often leaves both partners vulnerable to relapse.

Couples Rehab is a national addiction treatment placement and referral network — not a treatment facility. We help couples find licensed, credentialed treatment providers that specialize in joint admission and couples-centered recovery. Our care navigators verify insurance benefits, assess each partner’s clinical needs, and coordinate admission into programs equipped to safely treat both individuals together. Treatment is delivered by independent clinical teams at the facilities we connect families to.

What Is Prescription Drug Addiction?

Prescription drug addiction — formally classified as a substance use disorder (SUD) — develops when repeated exposure to a medication produces neurological changes that drive compulsive use despite negative consequences. Three prescription drug classes account for the majority of dependence cases: opioid analgesics, central nervous system (CNS) depressants (including benzodiazepines and sleep medications), and CNS stimulants (including ADHD medications and prescription amphetamines).

Physical dependence is not the same as addiction, but it is frequently the gateway. When the brain adapts to the presence of a substance, stopping suddenly triggers withdrawal — a set of symptoms that can range from deeply uncomfortable to medically dangerous, depending on the drug class and the duration and intensity of use. This withdrawal experience is often what drives continued use even after someone genuinely wants to stop. Understanding which prescription drugs require medically supervised detox is the first clinical decision in the recovery process.

Can Couples Attend Prescription Drug Rehab Together?

Joint admission to prescription drug rehab is regularly possible, though it is never guaranteed in advance and depends on a set of clinical factors that an intake team evaluates before admission. The following variables typically inform that evaluation:

• Relationship safety screening: Accredited programs require a structured assessment for intimate partner violence (IPV) before joint admission. If there is any history of physical, emotional, or coercive control, the clinical team evaluates whether co-treatment is safe and therapeutic or whether separate tracks are indicated, at least initially.
• Withdrawal severity: Each partner’s substance, dose, duration of use, and medical history determines their individual level of care need. A partner requiring intensive medical monitoring may need a higher level of care than the other, which can affect the logistics of joint admission.
• Dual diagnosis complexity: Co-occurring mental health conditions — anxiety, depression, PTSD, ADHD, personality disorders — are common among people with prescription drug dependence. Programs with integrated psychiatric services can treat both partners’ presentations alongside the substance work.
• Motivation and readiness: Recovery works best when both partners are genuinely motivated. Programs evaluate whether treatment is voluntary and whether each individual has goals independent of the relationship.
• Facility policy and bed availability: Not all licensed treatment providers accept couples. Joint bed availability is confirmed at the time of admission coordination, not in advance.

When all clinical factors align, treating together offers real advantages: shared accountability, synchronized timelines, couples therapy integrated into the program, and the opportunity to rebuild communication and trust in a structured clinical environment. Our care navigators can help you understand what joint treatment would look like for your specific situation. Call (888) 500-2110 to begin that conversation.

Types of Prescription Drugs That Lead to Addiction

Opioid Analgesics

Prescription opioids — including oxycodone (OxyContin, Percocet), hydrocodone (Vicodin), codeine, morphine, and fentanyl in patch or lozenge form — are the most commonly misused prescription drug class in the United States. According to CDC overdose prevention data, prescription opioids remain a leading cause of drug overdose deaths even as illicit fentanyl has surged. Physical dependence can develop within four to eight weeks of regular therapeutic use at prescribed doses; misuse accelerates that timeline significantly.

Opioid use disorder involving prescription opioids is frequently the gateway to illicit opioid use, including heroin and street fentanyl, as tolerance increases and prescriptions become harder to obtain. This escalation pattern is clinically well-documented and reinforces why early intervention — before the crossover to illicit supply — significantly improves outcomes.

Benzodiazepines and Prescription Sleep Medications

Benzodiazepines — alprazolam (Xanax), diazepam (Valium), lorazepam (Ativan), clonazepam (Klonopin) — are prescribed for anxiety, panic disorder, seizure conditions, and alcohol withdrawal management. Z-drugs (zolpidem/Ambien, eszopiclone/Lunesta) share a similar mechanism and withdrawal profile. Both classes act on GABA-A receptors, producing sedation and anxiety relief; when the brain compensates for chronic exposure, stopping abruptly can trigger life-threatening withdrawal including grand mal seizures.

Benzodiazepine and Z-drug dependence is often iatrogenic: it begins with a legitimate prescription and escalates gradually as tolerance develops and the original anxiety symptoms return with greater intensity between doses. Many people with benzodiazepine dependence do not recognize that their worsening anxiety between doses is withdrawal, not a recurrence of the underlying condition requiring more medication.

Prescription Stimulants

Amphetamine-based ADHD medications — amphetamine salts (Adderall), lisdexamfetamine (Vyvanse), and methylphenidate (Ritalin, Concerta) — carry significant misuse potential, particularly at doses above prescribed levels or when taken by people without ADHD. Stimulant use disorder produces a psychiatric withdrawal profile (crash, depression, fatigue, hypersomnia, dysphoria, and in severe cases stimulant-induced psychosis) rather than the pharmacological withdrawal seen with opioids or sedatives.

Gabapentinoids, Muscle Relaxants, and Tramadol

Gabapentinoids — gabapentin (Neurontin) and pregabalin (Lyrica) — are prescribed for nerve pain, anxiety, and adjunct seizure control and have emerged as a significant misuse drug class, with withdrawal that can include anxiety, insomnia, pain, and in some cases seizures. Carisoprodol (Soma) is metabolized in part to a barbiturate-like compound and carries its own dependence and withdrawal risk. Tramadol, a synthetic opioid analgesic, produces mixed opioid and serotonin/norepinephrine reuptake inhibitor withdrawal. Any assessment for prescription drug detox should capture the full pharmacological picture — every substance and supplement — to ensure safe management.

Withdrawal Symptoms by Prescription Drug Class

Opioid Withdrawal: Timeline and Symptoms

Opioid withdrawal is assessed clinically using the Clinical Opiate Withdrawal Scale (COWS), a structured 11-item instrument scoring symptoms from 0 to 48+. Scores of 5 to 12 indicate mild withdrawal; 13 to 24, moderate; 25 to 36, moderately severe; above 36, severe. COWS scoring guides medication dosing decisions throughout detox.

The withdrawal timeline varies by opioid half-life:

• Short-acting opioids (oxycodone, hydrocodone, heroin): Symptoms typically begin 8 to 24 hours after last use, peak at 36 to 72 hours, and resolve over 7 to 10 days without treatment. With buprenorphine induction, symptom burden is dramatically reduced within hours of the first dose.
• Long-acting opioids (methadone, extended-release formulations): Onset is delayed to 36 to 48 hours, peak extends to days 4 through 6, and the overall arc can last 2 to 3 weeks. Methadone taper is typically used for methadone withdrawal; abrupt cessation of high-dose methadone is medically discouraged.

Opioid withdrawal symptoms include anxiety, agitation, muscle aches and cramps, insomnia, sweating, goosebumps (piloerection), nausea, vomiting, diarrhea, and intense drug craving. While opioid withdrawal is not directly life-threatening for medically stable adults in the way that alcohol or benzodiazepine withdrawal is, the extreme discomfort drives relapse at very high rates without pharmacological support. Post-detox overdose risk is significantly elevated because tolerance resets during abstinence — any return to prior opioid doses can be fatal.

Benzodiazepine Withdrawal: Timeline and Symptoms

Benzodiazepine and Z-drug withdrawal is assessed using an adapted Clinical Institute Withdrawal Assessment (CIWA-Ar) protocol or benzodiazepine-specific variants. It shares the same core mechanism as alcohol withdrawal (GABA-A receptor upregulation) and carries the same seizure and delirium risk. Benzodiazepine withdrawal is medically serious and must never be managed without clinical supervision.

• Short-acting (alprazolam/Xanax, lorazepam/Ativan): Symptoms emerge within 6 to 12 hours after last dose, peak at 24 to 72 hours, and may persist with protracted symptoms for weeks to months. Grand mal seizures are most likely within this window.
• Long-acting (diazepam/Valium, clonazepam/Klonopin): Symptom onset is delayed to 24 to 48 hours, but the prolonged half-life means a longer withdrawal arc — typically 2 to 4 weeks — is common.

Standard medical management involves a structured taper — typically using a long-acting benzodiazepine such as diazepam or chlordiazepoxide (Librium) — to gradually reduce GABA receptor stress while preventing seizure. Phenobarbital is used in some protocols as an alternative. Abrupt cessation of benzodiazepines after high-dose or long-duration use can cause status epilepticus and requires emergency medical intervention.

Stimulant Withdrawal: Timeline and Symptoms

Stimulant withdrawal is not pharmacologically dangerous in the way that sedative or opioid withdrawal is, but it carries significant psychiatric risk:

• Crash phase (first 24 to 72 hours): Profound fatigue, hypersomnia, increased appetite, depression, and emotional flatness. Suicidal ideation can emerge in this phase, particularly in people with a history of depression.
• Withdrawal phase (days 4 to 28): Continued dysphoria, anhedonia, low energy, impaired concentration, drug craving, and in some cases anxiety or irritability. Recovery of baseline dopamine function can take weeks to months depending on the intensity and duration of stimulant use.
• Stimulant-induced psychosis: High-dose or long-duration amphetamine use can cause paranoid psychosis that may persist beyond cessation. Psychiatric evaluation and, in some cases, antipsychotic medication are required.

Which Prescription Drugs Require Medical Detox?

Not every substance requires the same level of clinical monitoring during withdrawal, but prescription drug detox should always begin with a medical evaluation. The following reflects the clinical risk gradient across drug classes:

Always Requires Medical Supervision

• Benzodiazepines and Z-drugs: High-dose or long-duration use carries serious seizure and delirium risk. Medical detox is not optional.
• Prescription opioids at high doses or after extended use: Medication-assisted treatment (MAT) with buprenorphine or methadone, initiated under medical supervision, dramatically improves safety and retention. The American Society of Addiction Medicine (ASAM) endorses MAT initiation as the standard of care for moderate to severe opioid use disorder.
• Gabapentinoids at high doses: Gabapentin and pregabalin withdrawal can include seizures in cases of high-dose, long-duration use. A medical evaluation determines the appropriate taper protocol.
• Carisoprodol (Soma) and barbiturates: These share the alcohol/benzodiazepine withdrawal risk profile and require medical management.

Medically Recommended

• Prescription stimulants: While withdrawal is not pharmacologically dangerous, crash-phase suicidality warrants medical and psychiatric monitoring, especially in the first 72 hours.
• Tramadol: Produces mixed opioid and serotonergic withdrawal. Medical supervision prevents the small risk of tramadol withdrawal seizures and manages the complex symptom profile.
• Polysubstance dependence: Any combination of the above multiplies risk and complexity. Mixed benzodiazepine and opioid dependence requires careful sequencing and close monitoring.

Our care navigators can help you understand what level of care is appropriate based on the specific substances involved. We do not make final medical determinations — that responsibility belongs to the clinical team at the treating facility — but we can help you ask the right questions and find programs equipped to manage your situation. Call (888) 500-2110 to speak with a navigator now.

Medications Used in Prescription Drug Detox and Recovery

Opioid Detox and Medication-Assisted Treatment

Three FDA-approved medications form the backbone of opioid use disorder treatment:

• Buprenorphine (Suboxone, Subutex, Sublocade): A partial opioid agonist that binds tightly to mu-opioid receptors, relieving withdrawal and cravings while carrying a built-in ceiling effect that reduces overdose risk. Buprenorphine is typically initiated once COWS score reaches 8 to 12 (mild to moderate withdrawal) to avoid precipitated withdrawal. It can be used for detox (short taper) or as long-term maintenance therapy — ASAM endorses MAT for at least 12 months and often indefinitely based on individual response.
• Methadone: A full opioid agonist used in federally regulated opioid treatment programs. Methadone has the longest evidence base for reducing illicit opioid use, mortality, and criminal involvement. It is particularly appropriate for high-severity opioid use disorder and is dispensed daily at licensed clinics, with take-home doses earned over time.
• Naltrexone (Vivitrol): An opioid antagonist that completely blocks opioid receptor binding, making opioid use subjectively unrewarding. Extended-release injectable naltrexone (monthly injection) eliminates the adherence problems of oral tablets. Naltrexone requires complete opioid detoxification first — no opioids in the system for at least 7 to 10 days — or it will precipitate acute withdrawal.

Comfort medications commonly used alongside MAT include clonidine (for autonomic hyperactivity: sweating, elevated heart rate, anxiety), ondansetron or promethazine (nausea and vomiting), loperamide (diarrhea), non-opioid analgesics (muscle cramps), and hydroxyzine or trazodone (insomnia). Thiamine and folate supplementation are standard for anyone with significant alcohol co-use or nutritional depletion.

Benzodiazepine Detox Medications

The standard protocol for benzodiazepine detox is a structured taper — typically using a long-acting benzodiazepine such as diazepam (Valium) or chlordiazepoxide (Librium), or in some protocols, phenobarbital. The chosen agent is titrated to suppress withdrawal symptoms, then tapered gradually over days to weeks depending on the severity of dependence. Some programs extend the taper over months for severe, long-duration benzodiazepine dependence. Abrupt cessation of the taper can trigger breakthrough withdrawal seizures.

Stimulant Withdrawal Medications

No FDA-approved pharmacotherapy exists specifically for stimulant withdrawal. Clinicians may use bupropion (Wellbutrin) to support mood and energy recovery, mirtazapine for sleep and appetite restoration, or propranolol for anxiety. Antipsychotic medications (aripiprazole, quetiapine) are used when stimulant-induced psychosis is present. The primary intervention is supportive: nutritional restoration, regulated sleep, hydration, and psychiatric monitoring through the crash and early recovery phase.

Dual Diagnosis: Co-Occurring Mental Health Conditions

Prescription drug misuse and mental health conditions co-occur at high rates. According to SAMHSA’s National Survey on Drug Use and Health, approximately half of people with a substance use disorder also meet criteria for a co-occurring mental health condition. For couples with prescription drug dependence, the most common presentations include:

• Anxiety disorders and benzodiazepine dependence: Anxiety is the most common reason benzodiazepines are prescribed, and rebound anxiety during withdrawal is often more severe than the original anxiety disorder. Treatment requires integrated psychiatric care to safely taper the benzodiazepine while addressing the underlying anxiety with non-addictive medications (SSRIs, SNRIs, buspirone) and evidence-based therapy.
• Chronic pain and opioid use disorder: Many people with opioid dependence began with prescribed opioids for legitimate pain conditions. Integrated treatment addresses both the addiction and the underlying pain through multimodal pain management strategies, including physical therapy, non-opioid analgesics, nerve blocks, and behavioral pain management. MAT with buprenorphine also has evidence for pain management in OUD.
• ADHD and prescription stimulant misuse: ADHD is both a condition legitimately treated with stimulant medications and a risk factor for substance use disorder. When stimulant misuse develops in someone with genuine ADHD, the treatment question involves whether non-stimulant ADHD medications (atomoxetine/Strattera, viloxazine/Qelbree, guanfacine/Intuniv) can manage ADHD during early recovery, with stimulant re-evaluation after a period of sobriety.
• PTSD and substance use disorder: Trauma histories are among the most significant predictors of prescription drug misuse, both as self-medication and as a consequence of traumatic events. For couples, shared trauma histories or trauma within the relationship itself require specialized concurrent treatment. Our PTSD treatment for couples page covers this topic in depth.
• Depression and co-occurring substance use: Crash-phase stimulant withdrawal, post-acute opioid withdrawal syndrome (PAWS), and the demoralization of active addiction all produce depressive symptoms. Distinguishing substance-induced depression from an independent mood disorder requires a period of abstinence and careful clinical observation. Dual diagnosis programs are designed to make this distinction and treat both conditions simultaneously.

Programs with integrated dual diagnosis capability — combining addiction medicine with embedded psychiatric services — are the appropriate level of care for most couples with co-occurring presentations. Our navigators specifically screen for this capability when placing couples. Learn more about dual diagnosis treatment programs.

What Happens During Prescription Drug Detox for Couples?

Day 1: Intake and Comprehensive Medical Evaluation

Admission begins with a thorough medical and psychiatric intake. Clinicians collect a complete substance use history — every substance used, dose, frequency, duration, and most recent use — along with a medical history, mental health history, medications, allergies, and current vital signs. Laboratory panels typically include a comprehensive metabolic panel, complete blood count, liver function tests, urine drug screen, and any relevant serum levels. This data drives the initial detox protocol.

For couples, each partner undergoes an independent intake, including the IPV screening required for joint admission assessment. If both partners are admitted, they are assigned to the same facility and managed by adjacent clinical teams with shared case coordination.

Days 1 Through 3: Active Medical Monitoring and Medication Initiation

The first 72 hours carry the highest risk for opioid, benzodiazepine, and gabapentinoid withdrawal. Vital signs are monitored at regular intervals. Withdrawal scales — COWS for opioids, CIWA-Ar or equivalent for sedatives — are scored repeatedly to guide medication dosing adjustments.

Buprenorphine induction for opioid withdrawal typically begins within the first 24 hours once withdrawal has started, preventing the need to reach severe withdrawal before the first dose. Benzodiazepine taper protocols are initiated immediately and adjusted based on symptom scoring. Stimulant crash management focuses on supportive care, sleep, nutrition, and close psychiatric monitoring.

Days 4 Through 7: Stabilization and Safety Screening

By days 4 through 7, most acute withdrawal symptoms have diminished and the clinical team shifts focus to stabilization. Medication regimens are adjusted toward maintenance or continued taper. Psychiatric evaluation is completed to establish any dual diagnosis diagnoses and initiate non-addictive psychotropic medications where indicated. Safety screenings continue: suicide risk, IPV dynamics between partners, and medication safety in the shared environment.

Days 7 Through 10 and Beyond: Transition Planning

Detox alone is not a treatment for addiction — it is stabilization in preparation for treatment. The clinical team and case manager work with each partner to confirm the post-detox treatment plan: residential admission, outpatient level of care, medication regimen, psychiatric follow-up, and couples therapy schedule. Our navigators at Couples Rehab stay in contact through this process and help troubleshoot any gaps in the transition. Explore the couples detox admissions process for more detail on what to expect.

Inpatient vs. Outpatient Prescription Drug Rehab

Factor	Inpatient / Residential Rehab	Outpatient (PHP / IOP)
Living situation	24/7 on-site residence at the treatment facility	Sleep at home or in sober living; attend program daily or several times per week
Medical oversight	Around-the-clock nursing, daily physician oversight	Regular medication management; on-call nurse/provider
Best suited for	High medical complexity, severe dependence, co-occurring psychiatric conditions, unstable home environment, history of relapse in outpatient settings	Medical stability after detox, strong support system at home, work or family obligations, mild to moderate severity
Duration	Typically 30, 60, or 90 days	PHP: 20 to 30+ hours per week for 4 to 6 weeks; IOP: 9 to 15 hours per week for 8 to 12 weeks
Couples therapy	Integrated couples sessions and family therapy components commonly available	Couples therapy available as adjunct; coordination with individual therapists
Joint admission	Most compatible with joint admission due to shared residential space	Partners can attend the same program while living together; more logistical flexibility

The right level of care is determined by clinical assessment, not preference alone. A partner with active benzodiazepine dependence requiring a multi-week taper protocol is not clinically appropriate for outpatient care during the active detox phase. Our navigators can walk you through what each level of care looks like and what your insurance may cover. Call (888) 500-2110 for a confidential benefit verification.

Benefits of Recovering Together as a Couple

When both partners are navigating prescription drug recovery simultaneously, shared treatment offers advantages that individual rehab cannot replicate. Research in addiction medicine literature indicates that behavioral couples therapy (BCT) combined with individual addiction treatment produces better abstinence outcomes, fewer relationship-related relapses, and higher treatment satisfaction than individual treatment alone for partners in committed relationships. Key benefits include:

• Synchronized recovery timelines: When one partner completes detox and returns home while the other is still in active use, relapse risk for the returning partner is high. Joint treatment eliminates this dynamic.
• Shared accountability: Partners who recover together provide mutual support for medication adherence, meeting attendance, and aftercare planning in ways that create genuine accountability between people who know each other’s patterns.
• Relationship repair in a structured environment: Trust, communication, and the relational wounds caused by addiction can be addressed directly in couples therapy during treatment — not only after.
• Understanding enabling patterns: Joint treatment is the best setting to identify and interrupt enabling behaviors, codependency dynamics, and communication patterns that have sustained the addiction cycle.
• Shared aftercare planning: A coordinated aftercare plan that accounts for both partners — medication management, couples therapy, support group attendance, triggers in the shared home environment — is more sustainable than two separate disconnected plans.

None of these benefits are guaranteed, and they depend on the relationship being a safe and supportive context for recovery. If intimate partner violence is present or the relationship itself is a primary trigger for substance use, separate treatment tracks may be recommended initially. The IPV screening during intake is designed to make this determination carefully and compassionately. You can also learn more about couples therapy during addiction recovery.

How Insurance Covers Prescription Drug Rehab for Couples

The Mental Health Parity and Addiction Equity Act (MHPAEA) and the Affordable Care Act (ACA) require that most commercial insurance plans cover substance use disorder treatment at parity with medical and surgical benefits. Medicaid expansion states also cover treatment for eligible enrollees. What this means in practice:

• Medical detox is typically covered as an inpatient medical service when medically necessary — which benzodiazepine, opioid, and mixed-substance withdrawal clearly meets.
• Inpatient residential rehab requires prior authorization in most plans. Length of stay is reviewed against ASAM criteria, with initial authorizations commonly granted for 7 to 14 days and extended through concurrent review.
• PHP and IOP are outpatient services that most commercial plans cover with lower cost-sharing than inpatient. Step-down from inpatient is commonly pre-authorized as part of the discharge plan.
• Medication-assisted treatment (MAT) — buprenorphine, methadone, naltrexone — is covered under pharmacy and medical benefits depending on the plan; some plans require prior authorization for extended-release formulations like Sublocade or Vivitrol.

Coverage varies significantly by plan, state, and insurer. We cannot guarantee coverage outcomes before verification — but our navigators verify benefits before any commitment is made. If coverage is limited, we help families understand the appeals process, out-of-network options, and alternative pathways. Call (888) 500-2110 to begin a free, confidential insurance verification. You can also review our couples rehab admissions guide for a step-by-step overview.

How to Get Help Today: Next Steps for Couples

1. Call (888) 500-2110: A care navigator will answer 24 hours a day, 7 days a week. No appointment needed, no obligation. The first call is a confidential conversation about what you and your partner are experiencing and what options may be available.
2. Complete the Couples Assessment: Our Couples Assessment helps our team understand the clinical picture — substances involved, relationship history, insurance coverage, geographic preferences — so we can identify programs that fit your specific situation.
3. Benefit verification: With your permission, we verify your insurance benefits before any facility commitment. You will understand what is covered, what your estimated out-of-pocket responsibility may be, and what alternative pathways exist if coverage is limited.
4. Placement coordination: We identify licensed programs that accept couples, match your clinical profile, and have availability. We facilitate the intake process and help with logistical questions: what to bring, what to expect, how to manage work and family responsibilities during treatment.
5. Aftercare support: After admission, our team remains available. If questions arise during treatment or if you need to explore step-down options as you approach discharge, our navigators are a continued resource.

What to Expect After Prescription Drug Rehab

Recovery from prescription drug dependence is a process that extends well beyond detox and the initial treatment program. Understanding the full continuum helps couples set realistic expectations and prepare for the commitments that build lasting sobriety:

• Residential treatment (30 to 90+ days): The primary phase of structured treatment, combining individual therapy, group therapy, couples sessions, educational groups on addiction and recovery, and medication management.
• Partial hospitalization program (PHP — 4 to 6 weeks, 20+ hours per week): Day treatment with return to a structured sober living or home environment each night. PHP provides high clinical support while reintegrating daily life skills.
• Intensive outpatient program (IOP — 8 to 12 weeks, 9 to 15 hours per week): The step-down from PHP; maintains therapeutic support while allowing fuller reintegration of work, family, and daily responsibilities.
• Ongoing couples therapy: Individual and couples therapy continues as outpatient services long after the formal treatment episode ends. Many couples continue weekly or biweekly therapy for 12 to 24 months post-discharge.
• Peer support and mutual aid: Narcotics Anonymous (NA) and SMART Recovery are commonly recommended for prescription drug recovery. These communities provide the social support network that sustains recovery between formal therapy appointments.
• MAT continuation: For opioid use disorder, ASAM guidelines recommend continuing buprenorphine or methadone for at least 12 months following stabilization. Medication discontinuation decisions should be made jointly with the prescribing physician and should not be rushed.
• Relapse prevention planning: A written relapse prevention plan — identifying triggers, early warning signs, agreed-upon responses, and emergency contacts — developed during residential treatment is a critical tool for both partners to maintain together.

Recovery resources: If you or your partner are in crisis, call 911 for emergencies. Call or text 988 for mental health and substance use crisis support. For confidential help finding prescription drug rehab for couples, call (888) 500-2110 — our care navigators are available 24/7 and can begin the intake process on your first call. You can also visit our crisis support page for immediate resources.

Frequently Asked Questions: Prescription Drug Rehab for Couples

Can both partners be admitted to prescription drug rehab at the same time?

Joint admission is regularly possible and can be clinically beneficial when both partners are medically appropriate for the same level of care, the relationship is safe after IPV screening, and the facility has capacity. It is never guaranteed in advance. Call (888) 500-2110 to discuss your specific situation with a care navigator.

What if only one of us is dependent on prescription drugs?

One-partner treatment with couples-centered programming is also available. Many residential programs integrate family therapy and couples counseling even when only one partner is enrolled. The non-addicted partner’s participation in family therapy is associated with better outcomes for the partner in treatment and helps address codependency and communication patterns that can undermine recovery at home.

Is benzodiazepine withdrawal dangerous?

Yes. High-dose or long-duration benzodiazepine withdrawal can produce life-threatening grand mal seizures and delirium. Benzodiazepine detox must be managed under medical supervision with a structured taper protocol. Never stop benzodiazepines abruptly after extended use without medical guidance. If someone is experiencing severe withdrawal symptoms, call 911 immediately.

Is opioid withdrawal life-threatening?

Opioid withdrawal is not directly life-threatening for medically stable adults in the way alcohol or benzodiazepine withdrawal is, but it drives relapse at very high rates and carries significant risk of fatal overdose if someone relapses after a period of abstinence because tolerance resets during detox. Medically supervised detox with buprenorphine or methadone dramatically reduces both the discomfort and the relapse risk.

What is buprenorphine and is it needed for prescription opioid withdrawal?

Buprenorphine (Suboxone, Subutex, Sublocade) is a partial opioid agonist used to manage opioid withdrawal and as long-term maintenance therapy for opioid use disorder. ASAM guidelines support MAT as the standard of care for moderate to severe OUD. It significantly improves outcomes for most people with opioid use disorder and is standard in medically supervised detox programs.

How long does prescription drug rehab take?

Detox typically lasts 5 to 14 days depending on the substance and severity of dependence. Residential treatment is typically 30, 60, or 90 days; PHP runs 4 to 6 weeks; IOP runs 8 to 12 weeks. Continuing care — outpatient therapy, peer support, and medication management — extends for months to years. ASAM recommends treating addiction as a chronic condition requiring ongoing management rather than a one-time acute episode.

Does insurance cover prescription drug rehab for couples?

Most commercial insurance plans cover medically necessary substance use disorder treatment, including detox, inpatient residential, PHP, IOP, and MAT, under the Mental Health Parity and Addiction Equity Act. Coverage levels vary significantly by plan. Our navigators verify benefits before any commitment. Call (888) 500-2110 for a free, confidential insurance verification.

Can both partners receive buprenorphine (Suboxone) during treatment?

Yes, if both partners have opioid use disorder, each can be individually assessed and, if clinically appropriate, initiated on buprenorphine as part of their treatment. MAT decisions are made on an individual clinical basis. Both partners can be simultaneously enrolled in MAT at the same facility when joint admission is arranged.

What is the difference between detox and rehab?

Detox (medically managed withdrawal) is the process of safely removing a substance from the body while managing withdrawal symptoms. Rehab is the ongoing clinical work that follows detox: therapy, relapse prevention, dual diagnosis treatment, and recovery skill-building. Detox without subsequent rehab has very poor long-term outcomes. The two phases are complementary and sequential.

What if my partner refuses to go to rehab?

Options include structured intervention with or without a professional interventionist, motivational conversations guided by a counselor, and making your own treatment a priority regardless of your partner’s current willingness. Recovery does not require both partners to enter treatment at the same moment. See our guide on how to convince your partner to go to rehab.

Can we attend prescription drug rehab in a different state?

Yes. Geographic flexibility is one advantage of working with a national placement network. Traveling for treatment can provide distance from triggering environments and access to specialized programs. Insurance coverage for out-of-state treatment depends on your specific plan; our navigators verify coverage for out-of-state facilities as part of the benefits check.

What is post-acute withdrawal syndrome (PAWS)?

Post-acute withdrawal syndrome (PAWS) refers to a cluster of symptoms — low mood, sleep disturbances, cognitive fog, low energy, and emotional dysregulation — that can persist weeks to months after acute withdrawal resolves. PAWS is associated with opioid, benzodiazepine, alcohol, and stimulant recovery and is a significant relapse risk factor. Ongoing therapy, peer support, sleep, nutrition, and physical activity are the primary management tools.

What should we bring to prescription drug rehab?

Facilities typically provide a packing list at admission coordination. Generally: comfortable clothing for the duration of your stay, prescription medications in original bottles (clinical staff manage dispensing), photo ID, insurance cards, a list of emergency contacts, and personal comfort items consistent with facility policy. Electronics policies vary; many programs restrict or limit phone use during the early treatment phase.

Do I need to tell my employer I am going to rehab?

You are not legally required to disclose the reason for a medical absence to your employer. The Family and Medical Leave Act (FMLA) may protect eligible employees’ jobs for up to 12 weeks of leave for a serious health condition, which includes substance use disorder treatment, without requiring disclosure of the specific condition. We recommend consulting with HR or an employment attorney for guidance specific to your situation.

Is Xanax addiction treated differently from other prescription drug addictions?

Yes. Alprazolam (Xanax) is a short-acting benzodiazepine that produces particularly severe and rapid-onset withdrawal compared to longer-acting benzos. Standard management involves converting to a long-acting benzodiazepine equivalent and implementing a gradual taper. Protracted withdrawal symptoms — intermittent anxiety, insomnia, cognitive symptoms — can persist for months and require extended therapeutic support. See our Xanax addiction treatment for couples page for more detail.

What happens if one partner relapses during treatment?

Relapse during treatment is addressed clinically by the treatment team, not punitively. It may result in a level-of-care adjustment — for example, moving from outpatient to inpatient if the relapse indicates that a lower intensity of support is insufficient. Many people experience setbacks during recovery; what distinguishes sustained recovery is the clinical response to those setbacks.

Trusted Sources

• National Institute on Drug Abuse (NIDA) — Prescription Drug Misuse
• Centers for Disease Control and Prevention (CDC) — Overdose Prevention
• Substance Abuse and Mental Health Services Administration (SAMHSA) — National Survey on Drug Use and Health
• American Society of Addiction Medicine (ASAM) — Clinical Practice Guidelines
• SAMHSA National Helpline
• 988 Suicide and Crisis Lifeline

Editorial Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice, a clinical assessment, or a treatment recommendation. Couples Rehab is a national addiction treatment placement and referral network — not a treatment facility, licensed clinical provider, or medical practice. We coordinate access to licensed treatment providers; we do not deliver clinical care directly. The clinical information in this article reflects general standards of care and should not be applied to any individual situation without evaluation by a qualified healthcare professional. Coverage outcomes, in-network status, and joint placement availability cannot be guaranteed in advance. If you or someone you know is in immediate danger, call 911. For crisis support, call or text 988. To speak with a care navigator about treatment options, call (888) 500-2110.

Medically reviewed by the Couples Rehab Clinical Advisory Team | Last updated: June 2026